Drug Database
DI

diptheria and tetanus vaccine (Td pur)

✓ Approved

Novartis AG · 疫苗 · 疫苗

什么是 diptheria and tetanus vaccine?

diptheria and tetanus vaccine 是一种疫苗,由Novartis AG研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Td pur
公司Novartis AG
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

diptheria and tetanus vaccine 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsTetanus✓ Approved

相关研究文献

PubMedChina CDC weekly2026-11-18

Childhood Immunization Schedule for National Immunization Program Vaccines, China (Version 2026).

Administration National Disease Control And Prevention NDCAP, China National Health Commission Of The People's Republic Of NHCOTPRO

In June 2026, the National Disease Control and Prevention Administration and the National Health Commission issued the Childhood Immunization Schedule for National Immunization Program Vaccines (Version 2026). Compared with the 2021 version, the key updates include optimization of the five-dose Diphtheria-Tetanus-acellular Pertussis vaccine schedule (with the first dose advanced to 2 months of age and the fifth dose administered at 6 years of age); inclusion of the bivalent human papillomavirus vaccine in the National Immunization Program as a two-dose series for girls aged 13 years (Table 1); and expanded and refined vaccination guidance for children with medical conditions, including preterm and low-birthweight infants, children with allergies, children born to mothers living with human immunodeficiency virus, children with immune function abnormalities, jaundice, common congenital diseases, or common neurological diseases, and children receiving blood products. This English translation provides a reference for public health professionals.

PMID 43047791
阅读全文 →
PubMedCureus2026-11-18

Maternal Vaccine Receipt, Intentions, and Refusal Among Pregnant Women Attending Antenatal Care in Panama City: A Cross-Sectional Study.

Lucas Quintero Ana A, DeAntonio Rodrigo R, Escobar Luis L, Flores Luis Alberto LA et al.

Background/objectives Maternal vaccination surveys often combine willingness and receipt, potentially obscuring differences between these measures. We quantified self-reported vaccine receipt, intention without receipt, complete reported receipt, and refusal in an urban Panamanian convenience sample and examined their relationship with vaccination recommendation. Methods We analyzed an anonymous cross-sectional survey completed from March 26 to July 25, 2026, by 204 pregnant women aged 18 years or older recruited in health-related settings in Panama City. Self-reported receipt meant reporting at least one maternal vaccine during the current pregnancy. Intention without receipt meant planning at least one vaccine without reporting receipt of any specific vaccine. Complete reported receipt was the independent response "already received all," rather than verified completion of a vaccination schedule. Modified Poisson regression with robust variance estimated prevalence ratios (PRs). A secondary, post hoc evaluation examined six rating items without claiming formal questionnaire validation. Results The number of women who chose self-reported receipt was 128/204 (62.7%; exact 95% confidence interval (CI), 55.7-69.4), while the composite of receipt or intention was 190/204 (93.1%). Intention without receipt was reported by 62/204 (30.4%), complete reported receipt by 41/204 (20.1%), and refusal with coexisting receipt or intention by 92/204 (45.1%). Four participants reporting complete receipt did not report any vaccine-specific receipt. Refusal was reported for COVID-19 by 96/204 (47.1%), influenza by 11/204 (5.4%), tetanus, diphtheria, and acellular pertussis (Tdap) by 8/204 (3.9%), and respiratory syncytial virus (RSV) by 7/204 (3.4%). Receipt was reported by 126/172 (73.3%) participants with a vaccination recommendation versus 2/32 (6.2%) without one (adjusted PR, 11.28; 95% CI, 2.95-43.17). Three-item standardized Cronbach's alpha values were 0.699 and 0.728, with substantial ceiling effects and an unstable two-factor solution. Conclusions In this convenience sample, stated acceptance coexisted with the absence of reported receipt and vaccine-specific refusal. Recommendation was associated with receipt, but the estimate was imprecise and noncausal. These findings are not population estimates and support reporting recommendation, intention, receipt, and refusal separately. Intention without receipt does not establish subsequent failure to vaccinate.

PMID 43048589
阅读全文 →
PubMedJournal of nanobiotechnology2026-11-18

Baculovirus-based production of virus-like particles for avian influenza: development, immunogenicity, and cross-protection against H5 and H7 AIVs.

He Yanjuan Y, Dong Yajing Y, Kong Dexin D, Chen Huixin H et al.

The persistent threat of H5 and H7 highly pathogenic avian influenza (HPAI) necessitates effective broad-spectrum vaccines. This study systematically evaluated the immunogenicity and protective efficacy of H5N6 virus-like particle (H5N6-VLP) vaccine and subsequently developed a trivalent VLP vaccine (H5N6-H5N8-H7N9-VLP) using the baculovirus expression system (BEVS). Production of H5N6-VLP was optimized at a multiplicity of infection (MOI) of 0.1 to achieve efficient assembly. The H5N6-VLP vaccine induced potent immune responses in specific-pathogen-free (SPF) chickens, providing 100% protection against homologous H5N6-GD154 virus when the HA titer reached 9 log2. Compared with traditional inactivated vaccines, the H5N6-VLP vaccine induced faster humoral immune responses and higher CD8⁺ T cell proportions. The HI seroconversion rate was 30% on day 7 post-immunization (0% for inactivated vaccine), reached 100% by day 10, while it was only 80% on day 14 for the inactivated vaccine. Furthermore, the protective efficacy of the H5N6-VLP vaccine was associated with increased IFN‑γ expression and elevated proportions of B cells and CD8⁺ T cells. Although both vaccines provided complete homologous protection, the H5N6-VLP vaccine showed better cross-protection against the heterologous H5N1-D889 strain (70% vs. 40%). A delayed challenge experiment further demonstrated that the H5N6-VLP vaccine induced durable immunity, with HI titers remaining above the protective threshold and 100% protection against homologous challenge at 8 weeks post-immunization. Based on these findings, a trivalent H5N6-H5N8-H7N9-VLP vaccine was developed. The trivalent vaccine induced substantial antibody responses and provided complete protection against parental and circulating strains, with efficacy comparable to a commercial inactivated vaccine and no detectable antigenic interference between components. Our findings highlight the potential of the BEVS-derived H5N6-VLP vaccine, particularly its early antibody induction, which allows rapid flock protection during acute HPAI outbreaks, and its cross-reactivity against heterologous strains. Furthermore, the trivalent vaccine formulation extends the potential application of this VLP platform for broad-spectrum HPAI control.

PMID 43046102
阅读全文 →
PubMedBioinformatics and biology insights2026-11-18

Formulation of a Novel NS5A- and NS5B-Based Chimeric Vaccine Against Hepatitis C Virus: An Artificial Intelligence-Supported Approach.

Niknam Maryam M, Zohrabzadeh Maryam M, Hahashempour Ava A, Honari Jahromi Ali A et al.

We aimed to design a multiepitope vaccine against hepatitis C virus (HCV) with the potential to elicit broad protective immunity against diverse HCV genotypes through computational design.Method: One hundred sequences of the most widespread subtypes of HCV were retrieved from the Los Alamos National Laboratory database, and consensus sequences of the NS5A and NS5B proteins were generated to construct an efficient vaccine for human use. Numerous B-cell lymphocyte, cytotoxic T-lymphocyte and helper T-lymphocyte epitopes located in the conserved domains of HCV proteins and similar in human and mouse alleles were evaluated criteria for use in the vaccine construct. Population coverage analysis identified that substantial parts of the worldwide population carry epitopes and their corresponding alleles within their genome, which confirms that the vaccine candidate is an effective agent against this lethal disease. Codon optimization and in silico cloning of eukaryotic and prokaryotic vectors validated the strong expression of the vaccine construct in the host systems. Molecular docking analysis revealed favorable binding affinities between the vaccine construct and toll-like receptors, which confirmed the vaccine's capacity to induce robust and stable immune responses against the hepatitis C virus. We incorporated new bioinformatic methods to design multiepitope vaccine against HCV. The development of a vaccine targeting multi genotypes of HCV could potentially provide for long-term protection against infection and may mitigate the risk of drug resistance across various genotypes and subtypes. Current research emphasizes the need for a vaccine that can elicit comprehensive immune responses, including both neutralizing antibodies and T-cell responses, to effectively address the genetic diversity of the virus. Future experimental studies are essential to validate predicted immunogenicity, structural stability, and protective efficacy before clinical consideration.

PMID 43047676
阅读全文 →
PubMedWomen's health reports (New Rochelle, N.Y.)2026-11-18

Postpartum HPV vaccination uptake: attitudes, beliefs, and determinants of acceptance.

Currier Jessica J JJ, Gagliuso Amelia H AH, Myers Emily E, Nguyen Christine Gt CG et al.

High-risk human Papillomavirus (hrHPV) is associated with six cancers. Although vaccination rates in the United States are increasing, series completion remains below the Healthy People 2030 goal of 80%. Pregnant individuals are a population with low HPV vaccination coverage, with only 7.5%-15.5% of patients aged 18-26 years receiving HPV vaccination prior to delivery. The postpartum period represents an opportunity to initiate or complete the HPV vaccination series. This study examined knowledge, attitudes, and beliefs regarding HPV vaccination among previously unvaccinated postpartum individuals and compared perspectives between those who accepted and declined vaccination. Postpartum individuals aged 18-26 were offered HPV vaccination. Participants completed a survey and semi-structured interviews. Patient characteristics, including HPV knowledge, were compared between participants who accepted and declined vaccination. Qualitative thematic analysis identified factors influencing vaccine attitudes and beliefs. Among participants, 53% accepted HPV vaccination and 46% declined. HPV knowledge was lower among participants who accepted the vaccine compared to those who declined; although this difference was not statistically significant. Vaccine hesitancy was associated with concerns regarding safety, effectiveness, and the need for additional information. Qualitative findings indicated that belief in the vaccine's cancer prevention benefits facilitated vaccine acceptance. Frequent healthcare encounters during the perinatal period created opportunities for provider counseling and vaccine delivery. The perinatal period offers a critical opportunity to promote HPV vaccination through frequent health care encounters and opportunities for ongoing education. However, access alone may be insufficient to optimize vaccine uptake. Vaccine hesitancy remained a significant barrier, and the immediate postpartum period was not consistently perceived as an optimal time for vaccination among some individuals experiencing heightened stress or competing medical priorities. Strategies to increase postpartum HPV vaccination should prioritize strong provider recommendations, clear communication about the vaccine's cancer prevention benefits, and interventions that addres vaccine hesitancy and structural barriers to vaccination.

PMID 43048345
阅读全文 →
PubMedAmerican journal of cancer research2026-11-18

Advancements in vaccines against cancer stem cells (CSCs).

Aayush, Talebiashtiany Yasaman Y, Abubakar Bobbo Khadijat K, Manogaran Motharasan M et al.

Cancer stem cells (CSCs) are a significant problem in cancer treatment due to their ability to self-renew, differentiate, and migrate, thus initiating and maintaining extensive support for metastasis. One way to eliminate CSCs is by using CSC-specific targeting vaccines, which mainly utilise their unique CSC-associated antigens. The current potential vaccines against the CSCs are the Dendritic Cell (DC)-based vaccine, Nanoparticle (NP)-based vaccine, and iPSC (Induced Pluripotent Stem Cell)-based vaccine. Potential vaccines/immunotherapies, such as GM-CSF Surface-Modified vaccines and VLP-based xCT immunotherapy, are also discussed. This review aims to highlight the progress in vaccinology against CSCs and the current limitations of these vaccines, such as the tumour microenvironment (TME) and a higher proliferation rate responsible for the low efficacy of anti-CSC vaccines.

PMID 43048158
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多diptheria and tetanus vaccine